Antipsychotic agents: efficacy and safety in schizophrenia

References

• BuckleyPFTreatment of schizophrenia: let’s talk dollars and senseAm J Manag Care19984336938310178499
   PubMed Web of Science ®Google Scholar
• RiceDPThe economic impact of schizophreniaJ Clin Psychiatry199960Suppl 146 discussion 28–3010037163
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders4th edWashington DCAmerican Psychiatric Association1994
   Google Scholar
• LindenmayerJPBernstein-HymanRGrochowskiSFive-factor model of schizophrenia. Initial validationJ Nerv Ment Dis1994182116316387964671
   PubMed Web of Science ®Google Scholar
• BreierABergPHThe psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcomeBiol Psychiatry199946336136410435201
   PubMed Web of Science ®Google Scholar
• AppelbaumPSRobbinsPCRothLHDimensional approach to delusions: comparison across types and diagnosesAm J Psychiatry1999156121938194310588408
   PubMed Web of Science ®Google Scholar
• TandonRNasrallahHAKeshavanMSSchizophrenia, “just the facts” 4. Clinical features and conceptualizationSchizophr Res20091101–312319328655
   PubMed Web of Science ®Google Scholar
• KitamuraTOkazakiYFujinawaATakayanagiIKasaharaYDimensions of schizophrenic positive symptoms: an exploratory factor analysis investigationEur Arch Psychiatry Clin Neurosci199824831301359728731
   PubMed Web of Science ®Google Scholar
• FoussiasGRemingtonGNegative symptoms in schizophrenia: avolition and Occam’s razorSchizophr Bull201036235936918644851
   PubMed Web of Science ®Google Scholar
• LindenmayerJPBrownEBakerRWAn excitement subscale of the Positive and Negative Syndrome ScaleSchizophr Res2004682–333133715099614
   PubMed Web of Science ®Google Scholar
• SaykinAJGurRCGurRENeuropsychological function in schizophrenia. Selective impairment in memory and learningArch Gen Psychiatry19914876186242069492
   PubMed Web of Science ®Google Scholar
• LiebermanJATollefsonGTohenMComparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidolAm J Psychiatry200316081396140412900300
   PubMed Web of Science ®Google Scholar
• McCreadieRGSrinivasanTNPadmavatiRTharaRExtrapyramidal symptoms in unmedicated schizophreniaJ Psychiatr Res200539326126615725424
   PubMed Web of Science ®Google Scholar
• MarderSRGlynnSMWirshingWCMaintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomesAm J Psychiatry200316081405141212900301
   PubMed Web of Science ®Google Scholar
• LeuchtSCorvesCArbterDEngelRRLiCDavisJMSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysisLancet20093739657314119058842
   PubMed Web of Science ®Google Scholar
• LeuchtSKomossaKRummel-KlugeCA meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophreniaAm J Psychiatry2009166215216319015230
   PubMed Web of Science ®Google Scholar
• de OliveiraIRJuruenaMFTreatment of psychosis: 30 years of progressJ Clin Pharm Ther200631652353417176358
   PubMed Web of Science ®Google Scholar
• HerzMIMarderSRSchizophrenia: Comprehensive Treatment and ManagementPhiladelphiaLippincott Williams and Wilkins2002
   Google Scholar
• StahlSMStahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications3rd edNew YorkCambridge University Press2008
   Google Scholar
• RothBLShefflerDJKroezeWKMagic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophreniaNat Rev Drug Discov20043435335915060530
   PubMed Web of Science ®Google Scholar
• de OliveiraIRElkisHGattazWFAripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidolCNS Spectr20091429310219238124
   PubMed Web of Science ®Google Scholar
• MailmanRBMurthyVThird generation antipsychotic drugs: partial agonism or receptor functional selectivity?Curr Pharm Des201016548850119909227
   PubMed Web of Science ®Google Scholar
• KerwinRWOsborneSAntipsychotic drugsMedicine2000282325
   Google Scholar
• LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• MiyamotoSDuncanGEMarxCELiebermanJATreatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugsMol Psychiatry20051017910415289815
   PubMed Web of Science ®Google Scholar
• Ayuso-GutiérrezJLdel Río VegaJMFactors influencing relapse in the long-term course of schizophreniaSchizophr Res1997282–31992069468354
   PubMed Web of Science ®Google Scholar
• PerkinsDOPredictors of noncompliance in patients with schizophreniaJ Clin Psychiatry200263121121112812523871
   PubMed Web of Science ®Google Scholar
• ThiedaPBeardSRichterAKaneJAn economic review of compliance with medication therapy in the treatment of schizophreniaPsychiatr Serv200354450851612663838
   PubMed Web of Science ®Google Scholar
• Liu-SeifertHAdamsDHKinonBJDiscontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugsBMC Med200532116375765
   PubMed Web of Science ®Google Scholar
• HarveyPDRabinowitzJEerdekensMDavidsonMTreatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trialAm J Psychiatry2005162101888189516199835
   PubMed Web of Science ®Google Scholar
• RabinowitzJHarveyPDEerdekensMDavidsonMPremorbid functioning and treatment response in recent-onset schizophreniaBr J Psychiatry2006189313516816303
   PubMed Web of Science ®Google Scholar
• MeltzerHYRabinowitzJLeeMAAge at onset and gender of schizophrenic patients in relation to neuroleptic resistanceAm J Psychiatry199715444754829090333
   PubMed Web of Science ®Google Scholar
• UçokAPolatAGençACakirSTuranNDuration of untreated psychosis may predict acute treatment response in first-episode schizophreniaJ Psychiatr Res200438216316814757330
   PubMed Web of Science ®Google Scholar
• PerkinsDOGuHBotevaKLiebermanJARelationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysisAm J Psychiatry2005162101785180416199825
   PubMed Web of Science ®Google Scholar
• AlemanAKahnRSSeltenJPSex differences in the risk of schizophrenia: evidence from meta-analysisArch Gen Psychiatry200360656557112796219
   PubMed Web of Science ®Google Scholar
• CorrellCUMalhotraAKKaushikSMcMenimanMKaneJMEarly prediction of antipsychotic response in schizophreniaAm J Psychiatry2003160112063206514594760
   PubMed Web of Science ®Google Scholar
• LeuchtSBuschRKisslingWKaneJMEarly prediction of antipsychotic nonresponse among patients with schizophreniaJ Clin Psychiatry200768335236017388703
   PubMed Web of Science ®Google Scholar
• KinonBJChenLAscher-SvanumHPredicting response to atypical antipsychotics based on early response in the treatment of schizophreniaSchizophr Res20081021–323024018423985
   PubMed Web of Science ®Google Scholar
• NaberDLambertMThe CATIE and CUtLASS studies in schizophrenia: results and implications for cliniciansCNS Drugs200923864965919594194
   PubMed Web of Science ®Google Scholar
• JonesPBBarnesTRDaviesLRandomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)Arch Gen Psychiatry200663101079108717015810
   PubMed Web of Science ®Google Scholar
• KempASSchoolerNRKalaliAHWhat is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?Schizophr Bull201036350450918723840
   PubMed Web of Science ®Google Scholar
• KinonBJPottsAJWatsonSBPlacebo response in clinical trials with schizophrenia patientsCurr Opin Psychiatry201124210711321285702
   PubMed Web of Science ®Google Scholar
• WalshBTSeidmanSNSyskoRGouldMPlacebo response in studies of major depression: variable, substantial, and growingJAMA2002287141840184711939870
   PubMed Web of Science ®Google Scholar
• ThaseMEThe small specific effects of antidepressants in clinical trials: what do they mean to psychiatrists?Curr Psychiatry Rep201113647648221964929
   PubMed Web of Science ®Google Scholar
• McMahonRPKellyDLBoggsDLFeasibility of reducing the duration of placebo-controlled trials in schizophrenia researchSchizophr Bull200834229230118184634
   PubMed Web of Science ®Google Scholar
• KemmlerGHummerMWidschwendterCFleischhackerWWDropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysisArch Gen Psychiatry200562121305131216330718
   PubMed Web of Science ®Google Scholar
• LeberPThe use of placebo control groups in the assessment of psychiatric drugs: an historical contextBiol Psychiatry200047869970610773176
   PubMed Web of Science ®Google Scholar
• ArasGSuperiority, noninferiority, equivalence, and bioequivalence–revisitedDrug Inf J20013511571164
   Google Scholar
• StreinerDLAlternatives to placebo-controlled trialsCan J Neurol Sci200734Suppl 1S37S4117469680
   PubMed Web of Science ®Google Scholar
• OliveiraIRNunesPMCoutinhoDMSenaEPReview of the efficacy of placebo in comparative clinical trials between typical and atypical antipsychoticsRev Bras Psiquiatr2009311525619506777
   PubMed Web of Science ®Google Scholar
• OverallJEGorhamDRThe brief psychiatric rating scalePsychol Rep1962 10103799812
   Web of Science ®Google Scholar
• KaySRFiszbeinAOplerLAThe positive and negative syndrome scale (PANSS) for schizophreniaSchizophr Bull19871322612763616518
   PubMed Web of Science ®Google Scholar
• CorrellCUKishimotoTNielsenJKaneJMQuantifying clinical relevance in the treatment of schizophreniaClin Ther20113312B16B3922177377
   PubMed Web of Science ®Google Scholar
• LeuchtSKaneJMKisslingWHamannJEtschelEEngelRClinical implications of Brief Psychiatric Rating Scale scoresBr J Psychiatry200518736637116199797
   PubMed Web of Science ®Google Scholar
• LeuchtSKaneJMKisslingWHamannJEtschelEEngelRRWhat does the PANSS mean?Schizophr Res2005792–323123815982856
   PubMed Web of Science ®Google Scholar
• LeuchtSKaneJMEtschelEKisslingWHamannJEngelRRLinking the PANSS, BPRS, and CGI: clinical implicationsNeuropsychopharmacology200631102318232516823384
   PubMed Web of Science ®Google Scholar
• LeuchtSKaneJMMeasurement-based psychiatry: definitions of response, remission, stability, and relapse in schizophreniaJ Clin Psychiatry200667111813181417196063
   PubMed Web of Science ®Google Scholar
• LevineSZRabinowitzJEngelREtschelELeuchtSExtrapolation between measures of symptom severity and change: an examination of the PANSS and CGISchizophr Res2008981–331832217949948
   PubMed Web of Science ®Google Scholar
• GuyWClinical global impressionsGuyWECDEU Assessment Manual for PsychopharmacologyRockville, MDUS Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs1976
   Google Scholar
• AndreasenNCCarpenterWTJrKaneJMLasserRAMarderSRWeinbergerDRRemission in schizophrenia: proposed criteria and rationale for consensusAm J Psychiatry2005162344144915741458
   PubMed Web of Science ®Google Scholar
• AndreasenNCThe Scale for the Assessment of Positive Symptoms (SAPS)Iowa City, IAThe University of Iowa1984
   Google Scholar
• AndreasenNCThe Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundationsBr J Psychiatry Suppl1989749582695141
   PubMedGoogle Scholar
• DellvaMATranPTollefsonGDWentleyALBeasleyCMJrStandard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophreniaPsychiatr Serv19974812157115779406266
   PubMed Web of Science ®Google Scholar
• TranPVDellvaMATollefsonGDWentleyALBeasleyCMJrOral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychosesBr J Psychiatry19981724995059828990
   PubMed Web of Science ®Google Scholar
• CsernanskyJGMahmoudRBrennerRfor Risperidone-USA-79 Study GroupA comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophreniaN Engl J Med20023461162211777998
   PubMed Web of Science ®Google Scholar
• de SenaEPSantos-JesusRMiranda-ScippaAQuarantini LdeCOliveiraIRRelapse in patients with schizophrenia: a comparison between risperidone and haloperidolRev Bras Psiquiatr200325422022315328547
   PubMedGoogle Scholar
• SchoolerNRabinowitzJDavidsonMRisperidone and haloperidol in first-episode psychosis: a long-term randomized trialAm J Psychiatry2005162594795315863797
   PubMed Web of Science ®Google Scholar
• PeuskensJTrivediJMalyarovSPrevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patientsPsychiatry (Edgmont)2007411345020428302
   PubMedGoogle Scholar
• KramerMSimpsonGMaciulisVPaliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled studyJ Clin Psychopharmacol200727161417224706
   PubMed Web of Science ®Google Scholar
• AddingtonDAddingtonJSchisselBA depression rating scale for schizophrenicsSchizophr Res1990342472512278986
   PubMed Web of Science ®Google Scholar
• KarowANaberDSubjective well-being and quality of life under atypical antipsychotic treatmentPsychopharmacology (Berl)2002162131012107610
   PubMed Web of Science ®Google Scholar
• de HaanLNimwegenLAmelsvoortTDingemansPLinszenDImprovement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophreniaPharmacopsychiatry200841412512818651339
   PubMed Web of Science ®Google Scholar
• JuruenaMFde SenaEPde OliveiraIRSafety and tolerability of antipsychotics: focus on amisulprideDrug Healthc Patient Saf2010220521121701632
   PubMedGoogle Scholar
• JanssenBGaebelWHaerterMKomaharadiFLindelBWeinmannSEvaluation of factors influencing medication compliance in inpatient treatment of psychotic disordersPsychopharmacology (Berl)2006187222923616710714
   PubMed Web of Science ®Google Scholar
• OlfsonMMechanicDHansellSBoyerCAWalkupJWeidenPJPredicting medication noncompliance after hospital discharge among patients with schizophreniaPsychiatr Serv200051221622210655006
   PubMed Web of Science ®Google Scholar
• VorugantiLCorteseLOwyeumiLSwitching from conventional to novel antipsychotic drugs: results of a prospective naturalistic studySchizophr Res2002572–320120812223251
   PubMed Web of Science ®Google Scholar
• ThomasPAlptekinKGheorgheMMauriMOlivaresJMRiedelMManagement of patients presenting with acute psychotic episodes of schizophreniaCNS Drugs200923393212
   Web of Science ®Google Scholar
• PolliceRTomassiniAMalavoltaMSubjective and psychopathological response in patients under different antipsychotic treatments: are there differences in real clinical practice?J Biol Regul Homeost Agents2008221839118394321
   PubMed Web of Science ®Google Scholar
• RoccaPCrivelliBMarinoFMonginiTPortaleoneFBogettoFCorrelations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophreniaCompr Psychiatry200849217017618243890
   PubMed Web of Science ®Google Scholar
• Schennach-WolffRJägerMSeemüllerFAttitude towards adherence in patients with schizophrenia at dischargeJ Psychiatr Res200943161294130119505697
   PubMed Web of Science ®Google Scholar
• DiazENeuseESullivanMCPearsallHRWoodsSWAdherence to conventional and atypical antipsychotics after hospital dischargeJ Clin Psychiatry200465335436015096075
   PubMed Web of Science ®Google Scholar
• NaberDMoritzSLambertMImprovement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugsSchizophr Res2001501–2798811378316
   PubMed Web of Science ®Google Scholar
• NarvaezJMTwamleyEWMcKibbinCLHeatonRKPattersonTLSubjective and objective quality of life in schizophreniaSchizophr Res2008981–320120817919890
   PubMed Web of Science ®Google Scholar
• HuppertJDWeissKALimRPrattSSmithTEQuality of life in schizophrenia: contributions of anxiety and depressionSchizophr Res2001512–317118011518637
   PubMed Web of Science ®Google Scholar
• KimJHAnnJHKimMJRelationship between improvements of subjective well-being and depressive symptoms during acute treatment of schizophrenia with atypical antipsychoticsJ Clin Pharm Ther201136217217821366646
   PubMed Web of Science ®Google Scholar
• HanssonLDeterminants of quality of life in people with severe mental illnessActa Psychiatr Scand Suppl2006429465016445482
   PubMedGoogle Scholar
• EackSMNewhillCEPsychiatric symptoms and quality of life in schizophrenia: a meta-analysisSchizophr Bull20073351225123717204532
   PubMed Web of Science ®Google Scholar
• HoganTPAwadAGEastwoodRA self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validityPsychol Med19831311771836133297
   PubMed Web of Science ®Google Scholar
• NaberDA self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variablesInt Clin Psychopharmacol199510Suppl 31331388866775
   PubMed Web of Science ®Google Scholar
• WareJEJrSherbourneCDThe MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selectionMed Care19923064734831593914
   PubMed Web of Science ®Google Scholar
• EuroQol GroupEuroQol – a new facility for the measurement of health-related quality of lifeHealth Policy199016319920810109801
   PubMed Web of Science ®Google Scholar
• LeonACOlfsonMPorteraLFarberLSheehanDVAssessing psychiatric impairment in primary care with the Sheehan Disability ScaleInt J Psychiatry Med1997272931059565717
   PubMed Web of Science ®Google Scholar
• NuechterleinKHGreenMFKernRSThe MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validityAm J Psychiatry2008165220321318172019
   PubMed Web of Science ®Google Scholar
• VenturaJCienfuegosABoxerOBilderRClinical global impression of cognition in schizophrenia (CGI-CogS): reliability and validity of a co-primary measure of cognitionSchizophr Res20081061596917900866
   PubMed Web of Science ®Google Scholar
• PietrzakRHOlverJNormanTPiskulicDMaruffPSnyderPJA comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophreniaJ Clin Exp Neuropsychol200931784885919142774
   PubMed Web of Science ®Google Scholar
• CollieADarekarAWeissgerberGCognitive testing in early-phase clinical trials: development of a rapid computerized test battery and application in a simulated Phase I studyContemp Clin Trials200728439140017267292
   PubMed Web of Science ®Google Scholar
• KeefeRSPoeMWalkerTMKangJWHarveyPDThe Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacityAm J Psychiatry2006163342643216513863
   PubMed Web of Science ®Google Scholar
• WilkCMGoldJMBartkoJJTest-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophreniaAm J Psychiatry2002159583884411986139
   PubMed Web of Science ®Google Scholar
• KeefeRSGoldbergTEHarveyPDGoldJMPoeMPCoughenourLThe Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive batterySchizophr Res2004682–328329715099610
   PubMed Web of Science ®Google Scholar
• HurfordIMMarderSRKeefeRSReiseSPBilderRMA brief cognitive assessment tool for schizophrenia: construction of a tool for cliniciansSchizophr Bull201137353854519776205
   PubMed Web of Science ®Google Scholar
• KrausMSKeefeRSCognition as an outcome measure in schizophreniaBr J Psychiatry Suppl200750s46s5118019044
   PubMedGoogle Scholar
• NielsenRENielsenJAntipsychotic drug treatment for patients with schizophrenia: theoretical background, clinical considerations and patient preferencesClin Med Ther2009110531068
   Google Scholar
• NemeroffCBKinkeadBGoldsteinJQuetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosingJ Clin Psychiatry200263Suppl 1351112562141
   PubMed Web of Science ®Google Scholar
• JuruenaMFde SenaEPde OliveiraIRSpecific mechanism of action of amisulpride in the treatment of schizophrenia and correlation with clinical response and tolerabilityJ Receptor Ligand Channel Res201144955
   Google Scholar
• KapurSSeemanPDoes fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesisAm J Psychiatry2001158336036911229973
   PubMed Web of Science ®Google Scholar
• HendersonDCMileyKGlucose intolerance and diabetes in patients with schizophreniaMeyerJMNasrallahHAMedical Illness and Schizophrenia2nd edWashington, DCAmerican Psychiatric Publishing, Inc2009
   Google Scholar
• Rummel-KlugeCKomossaKSchwarzSHead-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysisSchizophr Res20101232–322523320692814
   PubMed Web of Science ®Google Scholar
• CorrellCUFredericksonAMKaneJMManuPEqually increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychoticsBipolar Disord200810778879719032710
   PubMed Web of Science ®Google Scholar